There is no established therapeutic regimen for treatment of
hypoparathyroidism during pregnancy. This is due particularly to uncertainty about the use of
vitamin D or its analogues, as in animal experiments teratogenic side-effects have been reported. Nevertheless,
vitamin D or its analogues are required to control
tetany predisposing to abortion and preterm labour. We herein report the course of two pregnancies in a hypoparathyroid woman treated with
calcitriol (
1,25(OH)2D3). Additionally, we describe the outcome of pregnancy in ten women receiving
calcitriol, reported to the
Drug Safety Department (DSD), Hoffmann-La Roche AG. A 29-year-old hypoparathyroid woman receiving chronic treatment with
calcitriol (0.25 microg/day) and
calcium (1.5 g/day) was referred in the 6th week of her first pregnancy.
Calcitriol was initially discontinued, but during the 20th week of pregnancy recurrent
tetany occurred (serum
calcium 1.74 mmol/l).
Calcitriol (0.25 microg/day) was added, stabilizing serum
calcium around 2.15 mmol/l with
1,25(OH)2D3 concentrations around 60 ng/l (normal range 35-80 ng/l). To maintain normocalcaemia the
calcitriol dose was increased to 0.5 microg/day during the 33rd week and to 0.75 microg/day shortly before delivery of a healthy girl in the 3 7th week. During her second pregnancy
calcitriol was given initially at a dose of 0.25 microg/day with further adaptation to 0.5 microg/day during the 20th and to 1.00 microg/day in the 31st week. Serum
calcium and
1,25(OH)2D3 were continually within the lower normal range. She gave birth to another healthy girl during the 39th week. In eight of the ten pregnancies reported to the DSD no adverse effects of
calcitriol (0.25-3.25 microg/day) were seen and healthy babies were delivered. In two retrospectively reported cases, serious adverse events were described: premature closure of the frontal fontanelle, and
stillbirth in the 20th week due to complex
fetal malformation respectively. However, in both cases the causative role of
calcitriol administration remains highly questionable. We conclude that, during pregnancy, management of maternal
hypoparathyroidism with
calcitriol and
calcium is feasible, if the
1,25(OH)2D3 concentrations are adapted to the physiological needs during pregnancy and serum
calcium levels are kept in the lower normal range.